Comparative studies showed prolonged recurrence-free survival with gestagens (306.2 months) and aromatase inhibitors (153.1 months), compared to no hormonal therapy (90.8 months), although side effects (depression, weight gain, fluid retention) may limit long-term use [68,69]. Here, CYP19A1 is linked to depressive disorder.